FR0010386334 - Common Stock

**KORI** gets a fundamental rating of **2** out of 10. The analysis compared the fundamentals against 22 industry peers in the **Health Care Providers & Services** industry. While **KORI** is still in line with the averages on profitability rating, there are concerns on its financial health. **KORI** is valued expensive and it does not seem to be growing.

In the past year **KORI** was profitable.

In the past year **KORI** had a positive cash flow from operations.

In the past 5 years **KORI** always reported a positive cash flow from operatings.

With a **Return On Assets** value of **0.15%**, **KORI** is not doing good in the industry: **76.19%** of the companies in the same industry are doing better.

The **Return On Equity** of **KORI** (**0.62%**) is worse than **76.19%** of its industry peers.

Industry Rank | Sector Rank | ||
---|---|---|---|

ROA | 0.15% | ||

ROE | 0.62% | ||

ROIC | 2.43% |

ROA(3y)0.36%

ROA(5y)0.75%

ROE(3y)1.49%

ROE(5y)2.76%

ROIC(3y)2.49%

ROIC(5y)3.01%

The **Gross Margin** of **KORI** (**92.07%**) is better than **95.24%** of its industry peers.

Industry Rank | Sector Rank | ||
---|---|---|---|

OM | 7.54% | ||

PM (TTM) | 0.5% | ||

GM | 92.07% |

OM growth 3Y-8.77%

OM growth 5Y-3.82%

PM growth 3Y-46.1%

PM growth 5Y-37.51%

GM growth 3Y-0.1%

GM growth 5Y0.03%

The debt/assets ratio for **KORI** has been reduced compared to a year ago.

Based on the Altman-Z score of **0.51**, we must say that **KORI** is in the distress zone and has some risk of bankruptcy.

Industry Rank | Sector Rank | ||
---|---|---|---|

Debt/Equity | 1.96 | ||

Debt/FCF | 34.46 | ||

Altman-Z | 0.51 |

ROIC/WACC0.82

WACC2.97%

A Quick Ratio of **0.62** indicates that **KORI** may have some problems paying its short term obligations.

Industry Rank | Sector Rank | ||
---|---|---|---|

Current Ratio | 0.63 | ||

Quick Ratio | 0.62 |

The earnings per share for **KORI** have decreased strongly by **-77.10%** in the last year.

The **Revenue** has been growing slightly by **7.27%** in the past year.

EPS 1Y (TTM)-77.1%

EPS 3Y-46.73%

EPS 5Y-36.91%

EPS Q2Q%-85.96%

Revenue 1Y (TTM)7.27%

Revenue growth 3Y7.1%

Revenue growth 5Y7.23%

Sales Q2Q%6.66%

Based on estimates for the next years, **KORI** will show a small growth in **Revenue**. The Revenue will grow by **5.00%** on average per year.

EPS Next Y-69.88%

EPS Next 2Y-27.27%

EPS Next 3Y-17.31%

EPS Next 5YN/A

Revenue Next Year8.42%

Revenue Next 2Y7.06%

Revenue Next 3Y6.39%

Revenue Next 5Y5%

The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.

The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.

The **Price/Earnings** ratio is **38.74**, which means the current valuation is very expensive for **KORI**.

Based on the **Price/Earnings** ratio, **KORI** is valued a bit more expensive than 76.19% of the companies in the same industry.

Compared to an average S&P500 **Price/Earnings** ratio of **28.24**, **KORI** is valued a bit more expensive.

Based on the **Price/Forward Earnings** ratio, **KORI** is valued a bit more expensive than 66.67% of the companies in the same industry.

Compared to an average S&P500 **Price/Forward Earnings** ratio of **19.93**, **KORI** is valued a bit more expensive.

Industry Rank | Sector Rank | ||
---|---|---|---|

PE | 38.74 | ||

Fwd PE | 24.99 |

Based on the **Enterprise Value to EBITDA** ratio, **KORI** is valued a bit cheaper than the industry average as 61.90% of the companies are valued more expensively.

Industry Rank | Sector Rank | ||
---|---|---|---|

P/FCF | 3.27 | ||

EV/EBITDA | 8.71 |

A cheap valuation may be justified as **KORI**'s earnings are expected to decrease with **-17.31%** in the coming years.

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y-27.27%

EPS Next 3Y-17.31%

Compared to an average industry **Dividend Yield** of **2.07**, **KORI** pays a better dividend. On top of this **KORI** pays more dividend than 80.95% of the companies listed in the same industry.

Compared to an average S&P500 **Dividend Yield** of **2.37**, **KORI** pays a bit more dividend than the S&P500 average.

Industry Rank | Sector Rank | ||
---|---|---|---|

Dividend Yield | 3.27% |

On average, the dividend of **KORI** grows each year by **10.51%**, which is quite nice.

Dividend Growth(5Y)10.51%

Div Incr Years0

Div Non Decr Years0

The **Dividend Rate** of **KORI** has been growing, while earnings will be declining. This means the dividend growth is most likely not sustainable.

DP262.13%

EPS Next 2Y-27.27%

EPS Next 3Y-17.31%

**KORIAN**

EPA:KORI (6/19/2023, 7:00:00 PM)

**7.36**

**-0.29 (-3.79%) **

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupHealth Care Equipment & Services

GICS IndustryHealth Care Providers & Services

Earnings (Last)

Earnings (Next)

Inst Owners

Inst Owner Change

Ins Owners

Ins Owner Change

Market Cap783.53M

Analysts

Price Target

Dividend

Industry Rank | Sector Rank | ||
---|---|---|---|

Dividend Yield | 3.27% |

Dividend Growth(5Y)

DP

Div Incr Years

Div Non Decr Years

Ex-Date

Surprises & Revisions

EPS beat(2)

Avg EPS beat(2)

Min EPS beat(2)

Max EPS beat(2)

EPS beat(4)

Avg EPS beat(4)

Min EPS beat(4)

Max EPS beat(4)

EPS beat(8)

Avg EPS beat(8)

EPS beat(12)

Avg EPS beat(12)

EPS beat(16)

Avg EPS beat(16)

Revenue beat(2)

Avg Revenue beat(2)

Min Revenue beat(2)

Max Revenue beat(2)

Revenue beat(4)

Avg Revenue beat(4)

Min Revenue beat(4)

Max Revenue beat(4)

Revenue beat(8)

Avg Revenue beat(8)

Revenue beat(12)

Avg Revenue beat(12)

Revenue beat(16)

Avg Revenue beat(16)

PT rev (1m)

PT rev (3m)

EPS NQ rev (1m)

EPS NQ rev (3m)

EPS NY rev (1m)

EPS NY rev (3m)

Revenue NQ rev (1m)

Revenue NQ rev (3m)

Revenue NY rev (1m)

Revenue NY rev (3m)

Valuation

Industry Rank | Sector Rank | ||
---|---|---|---|

PE | 38.74 | ||

Fwd PE | 24.99 | ||

P/S | |||

P/FCF | |||

P/OCF | |||

P/B | |||

P/tB | |||

EV/EBITDA |

EPS(TTM)

EY

EPS(NY)

Fwd EY

FCF(TTM)

FCFY

OCF(TTM)

OCFY

SpS

BVpS

TBVpS

PEG (NY)N/A

PEG (5Y)N/A

Profitability

Industry Rank | Sector Rank | ||
---|---|---|---|

ROA | 0.15% | ||

ROE | 0.62% | ||

ROCE | |||

ROIC | |||

ROICexc | |||

ROICexgc | |||

OM | 7.54% | ||

PM (TTM) | 0.5% | ||

GM | 92.07% | ||

FCFM |

ROA(3y)

ROA(5y)

ROE(3y)

ROE(5y)

ROIC(3y)

ROIC(5y)

ROICexc(3y)

ROICexc(5y)

ROICexgc(3y)

ROICexgc(5y)

ROCE(3y)

ROCE(5y)

ROICexcg growth 3Y

ROICexcg growth 5Y

ROICexc growth 3Y

ROICexc growth 5Y

OM growth 3Y

OM growth 5Y

PM growth 3Y

PM growth 5Y

GM growth 3Y

GM growth 5Y

F-Score

Asset Turnover0.3

Health

Industry Rank | Sector Rank | ||
---|---|---|---|

Debt/Equity | 1.96 | ||

Debt/FCF | |||

Debt/EBITDA | |||

Cap/Depr | |||

Cap/Sales | |||

Interest Coverage | |||

Cash Conversion | |||

Profit Quality | |||

Current Ratio | 0.63 | ||

Quick Ratio | 0.62 | ||

Altman-Z |

F-Score

WACC

ROIC/WACC

Cap/Depr(3y)

Cap/Depr(5y)

Cap/Sales(3y)

Cap/Sales(5y)

Profit Quality(3y)

Profit Quality(5y)

High Growth Momentum

Growth

EPS 1Y (TTM)-77.1%

EPS 3Y-46.73%

EPS 5Y

EPS Q2Q%

EPS Next Y-69.88%

EPS Next 2Y

EPS Next 3Y

EPS Next 5Y

Revenue 1Y (TTM)7.27%

Revenue growth 3Y7.1%

Revenue growth 5Y

Sales Q2Q%

Revenue Next Year

Revenue Next 2Y

Revenue Next 3Y

Revenue Next 5Y

EBIT growth 1Y

EBIT growth 3Y

EBIT growth 5Y

EBIT Next Year

EBIT Next 3Y

EBIT Next 5Y

FCF growth 1Y

FCF growth 3Y

FCF growth 5Y

OCF growth 1Y

OCF growth 3Y

OCF growth 5Y